Agreen Hadadi1, Katherine Er Smith1, Limeng Wan2, Jacqueline R Brown3, Greta Russler4, Lauren Yantorni4, Sarah Caulfield4, Jennifer Lafollette5, Melvin Moore6, Omer Kucuk6, Bradley Carthon6, Bassel Nazha6, Yuan Liu2, Mehmet A Bilen7. 1. Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA. 2. Departments of Biostatistics and Bioinformatics, Emory University, Atlanta, GA. 3. Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA; Department of Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA. 4. Department of Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA. 5. Grady Cancer Center for Excellence, Grady Memorial Hospital, Atlanta, GA. 6. Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA; Department of Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA; Grady Cancer Center for Excellence, Grady Memorial Hospital, Atlanta, GA. 7. Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA; Department of Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA; Grady Cancer Center for Excellence, Grady Memorial Hospital, Atlanta, GA. Electronic address: mehmet.a.bilen@emory.edu.
Abstract
BACKGROUND: Biomarkers have the potential to provide clinical guidance, but there is limited data for biomarkers in metastatic hormone sensitive prostate cancer (mHSPC). METHODS: We performed a retrospective multicenter review from Winship Cancer Institute at Emory University and Georgia Cancer Center for Excellence at Grady Memorial Hospital (2014-2020) in the United States of America (USA). We collected demographics, disease characteristics, and laboratory data, including complete blood counts (CBC) at the start of upfront therapy. We evaluated overall survival (OS) and progression-free survival (PFS) associated with baseline lab values. RESULTS: 165 patients were included with a median follow-up time of 33.5 months (mo). 105 (63.6%) had Gleason scores of 8-10 and 108 (65.9%) were classified as high-volume disease. 92 patients received upfront docetaxel (55.8%) and 73 received upfront abiraterone (44.2%). Univariate analyses (UVA) and multivariable analyses (MVA) identified worse clinical outcomes (CO) associated with elevated basophils and basophil-to-lymphocyte ratio (BLR). Based on MVA, elevated basophils (defined as ≥0.1, optimal cut) were associated with a hazard ratio (HR) of 3.51 (95% CI 1.65-7.43, P 0.001) for OS and HR of 1.88 (95% CI 1.05-3.38, P 0.034) for PFS. Our MVA also found that BLR ≥0.0142 was associated with HR 2.11 (95% CI 1.09-4.10, P 0.028) for OS; however, PFS was not statistically significant. CONCLUSION: We conclude that elevated baseline basophils and BLR are associated with worse clinical outcomes in mHSPC. Although results require further validation, BLR is a potential prognostic biomarker.
BACKGROUND: Biomarkers have the potential to provide clinical guidance, but there is limited data for biomarkers in metastatic hormone sensitive prostate cancer (mHSPC). METHODS: We performed a retrospective multicenter review from Winship Cancer Institute at Emory University and Georgia Cancer Center for Excellence at Grady Memorial Hospital (2014-2020) in the United States of America (USA). We collected demographics, disease characteristics, and laboratory data, including complete blood counts (CBC) at the start of upfront therapy. We evaluated overall survival (OS) and progression-free survival (PFS) associated with baseline lab values. RESULTS: 165 patients were included with a median follow-up time of 33.5 months (mo). 105 (63.6%) had Gleason scores of 8-10 and 108 (65.9%) were classified as high-volume disease. 92 patients received upfront docetaxel (55.8%) and 73 received upfront abiraterone (44.2%). Univariate analyses (UVA) and multivariable analyses (MVA) identified worse clinical outcomes (CO) associated with elevated basophils and basophil-to-lymphocyte ratio (BLR). Based on MVA, elevated basophils (defined as ≥0.1, optimal cut) were associated with a hazard ratio (HR) of 3.51 (95% CI 1.65-7.43, P 0.001) for OS and HR of 1.88 (95% CI 1.05-3.38, P 0.034) for PFS. Our MVA also found that BLR ≥0.0142 was associated with HR 2.11 (95% CI 1.09-4.10, P 0.028) for OS; however, PFS was not statistically significant. CONCLUSION: We conclude that elevated baseline basophils and BLR are associated with worse clinical outcomes in mHSPC. Although results require further validation, BLR is a potential prognostic biomarker.
Authors: Matthew R Smith; Fred Saad; Simon Chowdhury; Stéphane Oudard; Boris A Hadaschik; Julie N Graff; David Olmos; Paul N Mainwaring; Ji Youl Lee; Hiroji Uemura; Angela Lopez-Gitlitz; Géralyn C Trudel; Byron M Espina; Youyi Shu; Youn C Park; Wayne R Rackoff; Margaret K Yu; Eric J Small Journal: N Engl J Med Date: 2018-02-08 Impact factor: 91.245
Authors: Mehmet A Bilen; Dylan J Martini; Yuan Liu; Colleen Lewis; Hannah H Collins; Julie M Shabto; Mehmet Akce; Haydn T Kissick; Bradley C Carthon; Walid L Shaib; Olatunji B Alese; Rathi N Pillai; Conor E Steuer; Christina S Wu; David H Lawson; Ragini R Kudchadkar; Bassel F El-Rayes; Viraj A Master; Suresh S Ramalingam; Taofeek K Owonikoko; R Donald Harvey Journal: Cancer Date: 2018-10-17 Impact factor: 6.860
Authors: M Ferro; G Di Lorenzo; M D Vartolomei; D Bruzzese; F Cantiello; G Lucarelli; G Musi; S Di Stasi; R Hurle; G Guazzoni; G M Busetto; A Gabriele; F Del Giudice; R Damiano; F Perri; S Perdona; P Verze; M Borghesi; R Schiavina; G L Almeida; P Bove; E Lima; R Autorino; N Crisan; A R Abu Farhan; M Battaglia; G I Russo; Vincenzo Ieluzzi; G Morgia; P De Placido; D Terracciano; A Cimmino; L Scafuri; V Mirone; O De Cobelli; S Shariat; Guru Sonpavde; C Buonerba Journal: World J Urol Date: 2019-04-16 Impact factor: 4.226
Authors: Karim Fizazi; Stéphanie Foulon; Joan Carles; Guilhem Roubaud; Ray McDermott; Aude Fléchon; Bertrand Tombal; Stéphane Supiot; Dominik Berthold; Philippe Ronchin; Gabriel Kacso; Gwenaëlle Gravis; Fabio Calabro; Jean-François Berdah; Ali Hasbini; Marlon Silva; Antoine Thiery-Vuillemin; Igor Latorzeff; Loïc Mourey; Brigitte Laguerre; Sophie Abadie-Lacourtoisie; Etienne Martin; Claude El Kouri; Anne Escande; Alvar Rosello; Nicolas Magne; Friederike Schlurmann; Frank Priou; Marie-Eve Chand-Fouche; Salvador Villà Freixa; Muhammad Jamaluddin; Isabelle Rieger; Alberto Bossi Journal: Lancet Date: 2022-04-08 Impact factor: 79.321
Authors: Arnoud J Templeton; Mairéad G McNamara; Boštjan Šeruga; Francisco E Vera-Badillo; Priya Aneja; Alberto Ocaña; Raya Leibowitz-Amit; Guru Sonpavde; Jennifer J Knox; Ben Tran; Ian F Tannock; Eitan Amir Journal: J Natl Cancer Inst Date: 2014-05-29 Impact factor: 13.506
Authors: Lucia De Monte; Sonja Wörmann; Emanuela Brunetto; Silvia Heltai; Gilda Magliacane; Michele Reni; Anna Maria Paganoni; Helios Recalde; Anna Mondino; Massimo Falconi; Francesca Aleotti; Gianpaolo Balzano; Hana Algül; Claudio Doglioni; Maria Pia Protti Journal: Cancer Res Date: 2016-02-12 Impact factor: 12.701